Prevalence of frailty at population level in European ADVANTAGE Joint Action Member States: a systematic review and meta-analysis by O’Caoimh, Rónán et al.
M
o
n
o
g
r
a
p
h
ic
 s
e
c
t
io
n
226
Prevalence of frailty at population level 
in European ADVANTAGE Joint Action 
Member States: a systematic review 
and meta-analysis
Rónán O’Caoimh1, Lucia Galluzzo2, Ángel Rodríguez-Laso3, Johan Van der Heyden4,  
Anette Hylen Ranhoff5, Maria Lamprini-Koula6, Marius Ciutan7, Luz López Samaniego8, 
Laure Carcaillon-Bentata9, Siobhán Kennelly1*, Aaron Liew1 on behalf of Work Package 5  
of the Joint Action ADVANTAGE
1Health Service Executive of Ireland (Social Care Division) and National University of Ireland (Discipline of 
Medicine), Galway, Ireland 
2Dipartimento Malattie Cardiovascolari, Dismetaboliche e Invecchiamento, Istituto Superiore di Sanità, 
Rome, Italy 
3Fundación para la Investigación Biomédica del Hospital Universitario de Getafe, Getafe, Spain 
4Sciensano, Brussels, Belgium 
5Nasjonalt Folkehelseinstitutt (Norwegian Institute of Public Health), Oslo, Norway 
6Society of Psychosocial Research and Intervention. Ionnina, Greece 
7Scoala Nationala de Sanatate Publica, Management si Perfectionare in Domeniul Sanitar, Bucharest,  
Romania 
8Fundación Progreso y Salud, Consejeria de Salud de la Junta de Andalucia, Sevilla, Spain 
9Santé Publique, Saint Maurice, France 
*Siobhán Kennelly is not a member of the ADVANTAGE Joint Action
Ann Ist Super Sanità 2018 | Vol. 54, No. 3: 226-238
DOI: 10.4415/ANN_18_03_10
INTRODUCTION
Frailty is an age-associated vulnerability to stressors 
that results in an increased risk of adverse healthcare 
outcomes [1]. Based on current ageing demographics 
[2], it is expected that the number of older adults with 
recognised frailty syndromes will increase such that 
frailty is now identified as an emerging public health pri-
ority [3]. Although the prevalence of frailty has been re-
ported to range between 4-59.1% in community-based 
studies [4], there is marked variation in these in terms 
of methodological approaches, rendering geographical 
comparisons unclear. Longitudinal studies on ageing 
have shown that frailty is more common with greater 
age, female gender and socioeconomic factors, particu-
larly lower education and less wealth [5], and that there 
is wide variation across European countries where data 
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Abstract
Introduction. Although frailty is common among community-dwelling older adults, its 
prevalence in Europe and how this varies between countries is unclear.
Methods. A systematic review and meta-analysis of literature on frailty prevalence in 22 
European countries involved in the Joint Action ADVANTAGE was conducted. 
Results. Sixty-two papers, representing 68 unique datasets were included. Meta-analysis 
showed an overall estimated frailty prevalence of 18% (95% confidence interval, CI, 15-
21%). The prevalence in community (n = 53) vs non-community based studies (n = 15) 
was 12% (95% CI 10-15%) and 45% (95% CI 27-63%), respectively. Pooled prevalence in 
community studies adopting a physical phenotype was 12% (95% CI 10-14%, n = 45) vs 
16% (95% CI 7-29%, n = 8) for all other definitions. Sub-analysis of a subgroup of studies 
assessed as high-quality (n = 47) gave a pooled estimate of 17% (95% CI 13-21%).
Conclusions. The considerable and significant heterogeneity found warrants the devel-
opment of common methodological approaches to provide accurate and comparable 
frailty prevalence estimates at population-level.
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are available [6]. Two large population-based longitudi-
nal studies, the Survey of Health and Retirement in Eu-
rope (SHARE) and the Study on Global AGEing and 
Adult Health (SAGE), reporting mean Frailty Index 
(FI) scores, found the lowest levels of frailty in Ireland, 
Greece and The Netherlands with the highest levels in 
Italy, Spain and Poland [5]. A recent systematic review 
in long-term (nursing home) care (LTC) estimated that 
half of residents aged ≥ 60 years can be classified as frail 
but noted that these studies were highly heterogeneous 
with mean prevalence of frailty ranging widely from 
19% to 75.6% [7]. Individual studies have examined 
frailty in other populations but most studies report-
ing prevalence rates are limited to community-based 
samples with little data available from other important 
healthcare settings such as general practice, hospitals 
(inpatient or outpatient), or home care.
In order for healthcare planners and policy makers at 
local, national and European level to design and imple-
ment appropriate services for older adults, there is a 
need to determine the current prevalence of frailty in 
different settings using data from well designed pop-
ulation-based studies. The Joint Action (JA) initiative 
on Frailty, also called ADVANTAGE, co-funded by 
the European Third Health Programme (2014-2020), 
grant number #724099, aims to develop a holistic and 
comprehensive strategic framework for the prevention 
and management of frailty at European level. This JA 
brings together partners from 22 European countries 
(see www.advantageja.eu). One of its tasks is to explore 
the current state of knowledge on the epidemiology of 
frailty reviewing the existing literature on prevalence. 
This systematic review and meta-analysis aims to sum-
marize and analyze the data on frailty prevalence in JA 
Member States (MSs). International data from non-JA 
MSs were also included, where available and relevant, 
to provide context and comparison.
METHODS
Data sources and search strategy
We conducted a systematic search of the literature 
published between the 1st of January 2002 and the 
30th of April 2017 using PubMed, Embase, CINAHL, 
MEDLINE, Opengrey and the Cochrane databases. 
Grey literature and data from ongoing or unpublished 
frailty projects funded by the European Union or reg-
istered with the European Innovation Partnership 
on Active and Healthy Ageing [8, 9] were included 
based on information provided by MS partners about 
unpublished data or materials available through web-
sites, reports, and academic thesis. Reference lists of 
included papers were also researched for relevant ar-
ticles. The review protocol was registered and pub-
lished in full on the Prospero website (protocol number 
CRD42017071866). This systematic review and meta-
analysis was performed according to the Preferred Re-
porting Items for Systematic Reviews and Meta-Anal-
yses (PRISMA) guidelines [10]. The following search 
terms were applied: (Prevalence OR Incidence OR Epi-
demiology) AND (Elderly OR Aged OR “Older adult$” 
OR “Older person$” OR Geriatric$) AND (Frailty OR 
Frail) AND (Population-based OR “Population based”) 
NOT (“Frailty model” OR “Frailty survival model”). Re-
sults relating to frailty incidence were then singled out 
and published in another paper of the present journal 
issue [11].
Inclusion and exclusion criteria
Prevalence of frailty was defined as the proportion of 
cases in a population in a specific moment (point preva-
lence) or over a specific period of time (period preva-
lence). Papers were included if they met all the follow-
ing criteria: 1) Described data relating to frailty using 
any definition of frailty, irrespective of the method of 
data collection or instrument used, 2) Included par-
ticipants aged ≥ 18 (no maximum limit), 3) Reported 
population-based prevalence data without a restriction 
on the setting i.e. findings that can be extrapolated to 
a larger population defined in terms of geographical 
area, age group and setting (e.g. general population, 
hospitals, and LTC). Data from specific settings, e.g. 
patients in geriatric wards, were included only if there 
was evidence that all individuals in the population could 
be recruited from that setting, 4) Reported data from a 
JA MS in English or any language of a MS partner, 5) 
Published data between the 1st of January 2002 and the 
30th of April 2017. Papers published before 2002 were 
included on a case-by-case basis if discovered opportu-
nistically and deemed relevant, 6) Presented data from 
original articles. Letters to the editor, abstract publica-
tions, conference proceedings, non-systematic reviews 
(narrative reviews etc.), and editorials were excluded. 
Relevant grey literature was included on a case by case 
basis. The following exclusion criteria were applied: 1) 
Replicated data, 2) not in English or language of JA 
partner, 3) not about the topic and 4) other reasons, 
including papers focusing on individuals with specific 
diseases. 
Data extraction
Two pairs of reviewers independently assessed stud-
ies for inclusion. A third reviewer settled any disagree-
ments. Data from articles assessed as eligible for inclu-
sion were extracted and analyzed by a second pair of 
reviewers. 
Quality and bias assessment
The Checklist for Prevalence Studies from the Jo-
anna Briggs Institute (JBI) Critical Appraisal tools for 
use in JBI Systematic Reviews was preliminarly used to 
assess the methodological quality of each study and to 
determine the extent to which a study addressed the 
possibility of bias in its design, conduct and analysis 
[12]. All papers selected for inclusion in the systematic 
review were subjected to rigorous appraisal by two inde-
pendent pairs of critical appraisers with disagreements 
settled by consensus. Risk of publication bias across 
studies was assessed using funnel plots and confirmed 
by Egger’s test; a symmetric funnel plot indicates low 
risk of bias across studies.
Data synthesis and analysis
We conducted an initial descriptive analysis of the 
studies, followed by meta-analysis if there were more 
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than three meta-analyzable datasets. Due to the ex-
pected inherent heterogeneity of the included stud-
ies, a meta-analysis using an a priori random-effects 
model was chosen. In addition, subgroup analyses 
were performed according to: 1) the country in which 
data were collected; 2) the setting in which data were 
collected (community versus non-community); 3) the 
tools used to define frailty; and (4) the level of qual-
ity of the study as assed by means of the JBI Critical 
Appraisal tool (higher quality versus less high-quality 
studies).
The Freeman-Tukey double arcsine method, via 
metaprop_one ftt command in STATA (version 14.0), was 
used to perform the meta-analysis, in order to stabilize 
the inherent variance due to the nature of prevalence 
studies [13, 14]. Heterogeneity was assessed with Hig-
gins’ I2 statistic to determine the extent of variation be-
tween studies. The following cut-offs for the degree of 
heterogeneity were used; I2 = 0-40%: might not be im-
portant; I2 = 30-60%: may represent moderate hetero-
geneity; I2 = 50-90%: may represent substantial hetero-
geneity; I2 = 75-100%: considerable heterogeneity [15]. 
The significance was determined using the χ2 test with a 
p-value of < 0.05 considered significant. 
RESULTS
The selection of relevant papers is depicted in a PRIS-
MA flow diagram (Figure 1). In summary, 68 unique 
datasets, derived from 62 papers reporting prevalence 
data, met the inclusion criteria and were included. The 
results from countries participating in the SHARE proj-
ect were abstracted from a single paper [6], though 
presented as country-level data for this review. In addi-
tion, two systematic reviews reporting frailty prevalence 
data in older community-dwellers [4] and nursing home 
residents [7], that included results from JA MSs, were 
used to obtain relevant studies. Most papers were pub-
lished since 2012 (52/68, 77%) and the majority evalu-
ated persons aged 65 or over. The characteristics of the 
included studies reporting prevalence rates of frailty are 
summarised in Table 1.
Data were found across multiple settings at popu-
lation level including primary care (n = 5), outpatient 
geriatric clinics (n = 4), LTC (n = 3), hospitals (n = 2), 
public health centres (n = 1) and in community-based 
samples (n = 53) recruited using observational, cross-
sectional or cohort designs. Fifteen (68%) of the JA 
MSs had at least one published study reporting data 
on frailty prevalence rates, with the greatest number of 
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Figure 1
PRISMA flow diagram for the systematic review and meta-analysis of studies on the prevalence of frailty at population level in 
ADVANTAGE Joint Action (JA) Member States.
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Table 1
Characteristics of studies reporting prevalence rates of frailty at population level in ADVANTAGE Joint Action (JA) Member States
Source Frailty 
prevalence
Number of 
participants
Setting Frailty 
definition
Age
(years)
Women
(%)
Austria
Dorner et al., 2014 [38] 54.1 133 Hospital - General 
inpatients
SHARE FI ≥ 65 60.9
Santos-Eggimann et al., 2009 [5] 10.8 707 Community SHARE FI ≥ 65 Not reported
Belgium
Hoeck et al., 2012 [39] 9.3 4777 Community CHS ≥ 65 56
Theou et al., 2013 [40] 20.0 3699 Community SHARE FI ≥ 50 54.5
Boeckxstaens et al., 2015 [41] 7.2 567 Community CHS ≥ 80 62.8
Finland
Koponen et al., 2013 [42] 11.4 605 Community CHS ≥ 75 70.1
France
Santos-Eggimann et al., 2009 [5] 15.0 687 Community SHARE FI ≥ 65 Not reported
Avila-Funes et al., 2008 [43] 7.0 6078 Community CHS ≥ 65 61.3
Cesari et al., 2012 [44] 2.9 523 Community CHS ≥ 60 51
de Souto Barreto et al., 2012 [45] 9.8 398 Community CHS ≥ 60 64.3
Soler et al., 2016 [46] 51.1 1648 Hospital - Geriatric 
Clinic
CHS ≥ 60 64.4
Le Cossec et al., 2016 [47] 12.3 11089 Community CHS ≥ 55 54.9
Le Cossec et al., 2016 [47] 11.1 4236 Community CHS ≥ 55 57
Germany
Santos-Eggimann et al., 2009 [5] 12.1 933 Community SHARE FI ≥ 65 Not reported
Saum et al., 2012 [48] 8.9 3,112 Community CHS ≥ 59 52.5
Dapp et al., 2014 [33] 15.8 1679 Community FI ≥ 60 62.1
Bollwein et al., 2013 [49] 15.5 206 Community CHS ≥ 75 66
Buttery et al., 2015 [20] 2.6 1843 Community CHS 65-79 50.1
Vogt et al., 2015 [50] 4.1 954 Community CHS ≥ 65 49.1
Greece
Santos-Eggimann et al., 2009 [5] 14.7 784 Community SHARE FI ≥ 65 Not reported
Italy
Ble et al., 2006 [51] 6.5 827 Community CHS ≥ 65 54.0
Gallucci et al., 2009 [52] 16.3 668 Community Other ≥ 70 53.4
Bilotta et al., 2010 [53] 38.0 302 Hospital - Geriatric 
Clinic
SOF ≥ 65 71.0
Solfrizzi et al., 2012 [54] 7.6 2581 Community CHS 65-84 45.2
Forti et al., 2014 [55] 7.2 766 Community SOF ≥ 65 53.4
Roppolo et al., 2015 [56] 12.7 267 Community CHS ≥ 65 59.9
Veronese et al., 2016 [57] 10.0 1754 Community CHS ≥ 65 64.0
Santos-Eggimann et al., 2009 [5] 23.0 833 Community SHARE FI ≥ 65 Not reported
Liotta et al., 2017 [58] 21.5 1331 Community Other ≥ 65 54.2
Ireland
O’Halloran et al., 2013 [19] 2.0 4858 Community FI ≥ 50 52
Ntlholang et al., 2014 [59] 32.0 257 Hospital - Geriatric 
Clinic/Day Hospital
SHARE FI NA 64.8
O’Caoimh et al., 2014 [60] 54.3 784 Public Health 
Centres
CFS ≥ 65 64.0
Kelly et al., 2016 [61] 41.5 1312 Community CFS ≥ 65 70.6
Continues
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Table 1
Continued
Source Frailty 
prevalence
Number of 
participants
Setting Frailty 
definition
Age
(years)
Women
(%)
Theou et al., 2013 [40] 15.0 1107 Community SHARE FI ≥ 50 53.7
The Netherlands
Santos-Eggimann et al., 2009 [5] 11.3 830 Community SHARE FI ≥ 65 Not reported
Peters et al., 2012 [62] 62.1 124 Nursing home GFI ≥ 65 62.9
Van Kempen et al., 2013 [63] 24.0 141 Primary Care Other ≥70 62.0
Metzelthin et al., 2014 [26] 36.0 1101 Primary Care GFI ≥ 70 Not reported
Etman et al., 2014 [64] 24.8 408 Community ISAR ≥ 65 52.9
Lahousse et al., 2014 [65] 5.9 2833 Community CHS ≥ 55 55.9
Cramm et al., 2014 [66] 4.9 869 Community TFI ≥ 70 57.1
Hoogendijk et al., 2014 [67] 10.8 1205 Community CHS ≥ 65 Not reported
Mijnarends et al., 2015 [68] 8.4 227 Community CHS ≥ 65 48.5
Op het Veld et al., 2015 [69] 8.7 8,684 Community CHS ≥ 65 53.2
Reijnierse et al., 2015 [70] 28.6 299 Hospital - Geriatric 
Clinic
CHS NA 66.0
Norway
Langholz et al., 2017 [71] 3.7 736 Community CHS ≥ 65 51.4
Poland
Matusik et al., 2012 [17] 75.6 86 Nursing home CFS ≥ 65 76.7
Theou et al., 2013 [40] 42.0 2425 Community SHARE FI ≥ 50 Not reported
Bieniek et al., 2016 [72] 54.2 325 Hospital - Geriatric 
Ward
CHS NA 67.0
Portugal
Duarte et al., 2014 [21] 60.0 50 Community CHS ≥ 100 84.0
Duarte & Paul et al., 2015 [73] 34.9 339 Community CHS ≥ 50 53.4
Romania
Olaroiu et al., 2014 [18] 75.0 215 Primary Care GFI ≥ 65 66.0
Spain
Alcala et al., 2010 [74] 10.3 814 Community CHS ≥ 65 51.4
Abizanda-Soler et al., 2011 [75] 16.5 993 Community CHS ≥ 70 60.5
Santos-Eggimann et al., 2009 [5] 27.3 816 Community SHARE FI ≥ 65 Not reported
Jürschik Gimenez et al., 2012 [76] 9.6 640 Community CHS ≥ 75 60.3
Ferrer et al., 2014 [77] 20.5 273 Community CHS 85 60.8
Garcia-Garcia et al., 2011 [78] 8.4 1667 Community CHS ≥ 65 56.1
Garre-Olmo et al., 2013 [79] 17.3 875 Community Other ≥ 75 58.2
León-Muñoz et al., 2014 [80] 4.2 1815 Community CHS ≥ 60 51.3
Gonzalez-Vaca, et al., 2014 [23] 68.8 324 Nursing home CHS ≥ 65 56.1
Acosta-Benito et al., 2016 [81] 17.8 146 Community FRAIL scale ≥ 70 54.7
Papiol et al., 2016 [27] 29.4 126 Primary Care CHS ≥ 75 47.0
UK
Hubbard et al., 2010 [82] 9.7 3055 Community CHS ≥ 65 56.0
Syddall et al., 2010 [83] 6.3 642 Community CHS 64-74 50.0
Bouillon et al., 2013 [84] 2.8 3895 Community CHS 45-69 27.0
Ramsay et al., 2015 [85] 19.0 1622 Community CHS 71-92 0
Palmer et al., 2017 [24] 3.9 8095 Primary Care CHS 50-65 54.0
CHS - Cardiovascular Health Study; CFS - Clinical Frailty Scale; FI - Frailty Index; FRAIL - Fatigue, Resistance, Ambulation, Illnesses, & Loss of Weight scale; GFI - 
Groningen Frailty Indicator; ISAR - Identification of Seniors at Risk tool;  SHARE FI - Survey of Health, Ageing and Retirement in Europe Frailty Instrument; SOF - Study 
of Osteoporotic Fractures Index; TFI - Tilburg Frailty Indicator; NA = Not Available
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studies found in Spain (n = 11) and The Netherlands 
(n = 11). Prevalence rates from Slovenia and Hungary 
were not included in the systematic review and meta-
analysis because only sex-specific rates were available 
(Hungary 11.4% for females and 5.4% for males; Slove-
nia 6.1% for females and 2.3% for males, data available 
from SHARE in adults aged ≥ 50 years [16]). No pub-
lished data were found for 5 JA MSs: Bulgaria, Croatia, 
Cyprus, Lithuania and Malta. 
Frailty prevalence rates varied by setting and popula-
tion characteristics. The highest rate was found among 
residents (≥ 65) in nursing homes in Poland (75.6%) 
[17] and patients (≥ 65) in primary care in Romania 
(75%) [18]. The lowest rate in longitudinal cohorts 
was shown in Ireland (2% in persons ≥ 50, according 
to a 32-item FI) [19], followed by Germany (2.6% in 
subjects aged 65-79, according to the Fried Frailty 
phenotype) [20]. Most of the community-based stud-
ies (48/53, 91%) reported prevalence rates lower than 
30%, though results ranged widely from 2% among 
subjects aged ≥ 50 in Ireland [19] to 60% in those aged 
≥ 100 years in Portugal [21], with a median prevalence 
of 10.8%, interquartile range (Q1-Q3) 7.2-16.5%. Two 
studies reported prevalence rates of 54% among hos-
pital inpatients, while outpatients’ studies reported 
figures approximating 30%. In LTC, the prevalence 
rate of frailty varied from 62.1% [22] and 68.8% [23] 
to 75.6% [17] for three studies that included patients 
aged ≥ 65 years. 
Only five studies [18, 24-27] reported the prevalence 
rate of frailty in primary care, which also varied by sam-
ple characteristics and frailty instrument-classification. 
Three out of the five studies reported a prevalence rate 
of approximately 30% [25-27] with evident outlier re-
sults in Romania (75% in those ≥ 65 measured with the 
Groningen Frailty Indicator (GFI) [18] and the Unit-
ed Kingdom (3.9%, although in a younger population 
ranging from 50-65 years old and measured with the 
Frailty phenotype) [24].
We included all 68 unique datasets in the initial meta-
analysis. The results showed that the overall estimated 
prevalence of frailty in JA MSs was 18% (95% CI 15-
21%; 68 datasets; 13 932 individuals; I2 = 99.36%, p < 
0.001) (Figure 2). The sub-analysis of studies from com-
munity-based studies, stratified by the tools used to de-
fine frailty, showed a lower prevalence of 12% (95% CI 
10-15%; 53 datasets, 10 821 individuals; I2 = 99.01%, p < 
0.001) (Figure 3). The estimated prevalence of frailty in 
non-community-based studies was considerably higher 
(45%; 95% CI 27-63%; 15 datasets; 3111 individuals; I2 
= 99.7%, p < 0.001) (Supplementary Figure 1 available 
online). Sub-analysis of individual MSs only including 
community-based studies showed the lowest prevalence 
rates in the UK (9% with 95% CI 3-17%), France (9% 
with 95% CI 7-12%) and Germany (9% with 95% CI 
5-14%). The highest estimated prevalence rates were 
found in Portugal (38% with 95% CI 33-43%) and Po-
land (42% with 95% CI 40-44%) (Supplementary Figure 
2 available online).
The estimated prevalence also varied depending on 
the tools used to define frailty status. The most com-
monly reported classification of frailty in JA MSs was 
the Fried frailty phenotype based on the findings of the 
Cardiovascular Health Study (CHS) [28] (n = 39/68 
= 57%). The SHARE Frailty Instrument (SHARE-FI) 
[29], which captures similar physical parameters was 
the next most commonly used (n = 12), followed by the 
Groningen Frailty Indicator (n = 3) [30], the Clinical 
Frailty Scale (n = 3) [31], the Study of Osteoporotic 
Fractures (SOF) Index (n = 2) [32], and others (n = 
9) including two studies that used a FI [19, 33]. The 
pooled prevalence according to the frailty classifications 
was estimated only for community studies; the CHS 
frailty phenotype had a lower estimated prevalence of 
10% (95% CI 8-11%; I2 99%; n = 33) compared to the 
similar SHARE FI, which had an estimated prevalence 
rate of 18% (95% CI 13-25%; I2 99%; n=10) (Figure 3). 
The two community-based studies using the FI had the 
lowest estimated rate: 4% (95% CI 4-5%; n = 2). Simi-
larly, comparing the prevalence for the 45 community-
based studies using measures of the physical phenotype, 
i.e. either CHS (n = 33), SHARE-FI (n = 10), SOF (n 
= 1) or FRAIL scale (n = 1) instruments, with studies 
using the other frailty classification approaches (n = 8) 
showed rates of 12% (95% CI 10-14%) and 16% (95% 
CI 7-29%) respectively (Supplementary Figure 3 avail-
able online). When an extreme outlier including only 
centenarians [21] was excluded from this sub-analysis, 
the pooled estimated prevalence for studies classifiying 
frailty using physical parameters was similar: 11% (95% 
CI 9-13%).
Using the JBI checklist, 47 of the 62 papers were 
classified as high quality, meeting all nine of the check-
list criteria, and were included in a subgroup analysis. 
Despite including only studies that were deemed of 
sufficiently high quality, the overall estimated preva-
lence was similar to that observed for all 62 papers 
(17%; 95% CI 13-21%) (Supplementary Figure 4 avail-
able online). 
There was considerable significant (p ≤ 0.05) hetero-
geneity among studies, which remained analysing stud-
ies by country or after dichotomizing them according to 
settings, tools used to define frailty and quality of the 
included studies. Generally, studies for each subgroup 
showed considerable heterogeneity, suggesting that dif-
ferences in the effect size of included studies do exist. 
The Higgins’ I2 remains unchanged following sub-anal-
yses, indicating the existence of variance derived from 
sources other than sampling error. Visual inspection of 
the funnel plots indicated that there was evidence of 
publication bias, which was confirmed by Egger test, 
with the exception of the sub-analysis for community-
based studies (results not shown). 
DISCUSSION
This systematic review found multiple published pa-
pers reporting on the prevalence rate of frailty in JA 
(ADVANTAGE) MSs, although there was consider-
able heterogeneity between studies in sample, setting 
and reporting. Our meta-analysis confirmed a relatively 
high pooled prevalence of 18% in all settings, which did 
not change considerably (17%) limiting the analysis to 
studies classified as of higher quality, albeit the CI wid-
ened. As expected, the highest prevalence rates were 
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Figure 2
Estimated prevalence of frailty at population level in ADVANTAGE Joint Action Member States, n = 68 data sets. 
ES = Effect Size
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Figure 3
Estimated prevalence of frailty at population level in ADVANTAGE Joint Action Member States by tools used to define frailty. Data 
from community-based studies only, n = 53.
ES = Effect Size; CFS = Clinical Frailty Scale; CHS=Cardiovascular Health Study; FI = Frailty Index; FRAIL = Fatigue, Resistance, Am-
bulation, Illnesses, & Loss of Weight scale; ISAR = Identification of Seniors at Risk tool; SHARE FI = Survey of Health, Ageing and 
Retirement in Europe Frailty Instrument; SOF = Study of Osteoporotic Fractures Index; TFI = Tilburg Frailty Indicator.
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from studies among hospital inpatients (around 50%) 
or set in LTC (more than 60%). Lower figures, around 
30%, were found in studies in primary care and out-
patient settings. The prevalence rates reported in com-
munity-based studies (i.e. removing those set in hos-
pital or LTC settings) also varied, ranging from 2 [19] 
to 60% [21] with a median rate of 10.8%; most studies 
reported prevalence rates < 30%. The meta-analysis of 
community-based studies yielded a pooled estimate of 
12%, consistent with the global weighted rate of 10.7% 
reported in community-based samples aged ≥ 65 years 
in 2012 [4] but lower than the prevalence rate of frailty 
in low and middle-income countries, which have re-
cently been reported at 17.4% [34]. As expected, rates 
in non-community settings were markedly higher than 
in community samples, with a pooled estimate of 45% 
(95% CI 27-63%). This likely reflects fluctuations in 
frailty status during acute illness where frailty scores 
are significantly higher than at baseline after admission 
[35] and the high prevalence of disability and chronic 
multi-morbidity in nursing homes is associated with 
high levels of frailty [7]. As expected we found signifi-
cant heterogeneity between studies in keeping with 
marked differences in the inclusion criteria. Moreover, 
the significant heterogeneity between studies remained 
irrespective of setting, confirming the differences evi-
dent in the systematic review. 
Overall, while multiple papers on frailty prevalence 
were available, most came from just five JA ADVAN-
TAGE countries (France, Germany, Italy, the Nether-
lands and Spain). Five countries belonging to the JA 
did not have prevalence data available. Poland seems 
to have an especially high prevalence rate, both in our 
review and in results from the SHARE data set [5]. The 
North-South divide between northern and southern 
European countries in terms of age and gender gradi-
ents of frailty, which have been reported previously [6], 
could not be verified by the present review due to the 
difficulties comparing the studies. 
The Frailty phenotype (CHS) was the most com-
monly used frailty classification, though again there 
was marked heterogeneity in approaches to classify 
frailty across studies. This has importance given that 
no single consensus definition of frailty is as yet ac-
cepted [36] and the two most commonly used methods 
to define the syndrome, the FI and the Frailty Pheno-
type, while complementary, are not interchangeable, 
given that they measure different constructs [37]. Our 
meta-analysis showed that the estimated prevalence 
was dependent on the approach used to define frailty. 
In the community setting, the most frequently re-
ported frailty model was the CHS phenotype (n = 33) 
[28], followed by the SHARE-FI (n = 10) [29]. The 
CHS criteria gave a lower prevalence of 10% (95% CI 
8-11%) compared to a higher prevalence of 18% (95% 
CI 13-25%) for the the SHARE-FI (Figure 3). Given 
the similarity between the two instruments [29], these 
results are unexpected but are likely explained by the 
high heterogeneity of the samples included in this re-
view. Only two studies reported results using the FI 
to classify frailty. This may reflect the more common 
usage of the Frailty Phenotype in Europe and the rela-
tive ease of gathering the five CHS variables to con-
struct this in clinical practice. The studies using the 
FI [19, 33] showed a lower estimated prevalence than 
those using the CHS criteria, different from the re-
sults of other studies where the FI consistently pro-
vides higher frailty rates [37]. This possibly occured by 
chance, given the limited number of studies using the 
FI to define frailty, but also likely reflects the differ-
ent approaches used to modify the original Fried con-
struct. However, the pooled estimate from studies us-
ing instruments capturing the physical phenotype (i.e. 
results from community-based studies using the CHS 
criteria, SHARE-FI, SOF and FRAIL scale) confirmed 
that this classification approach provides a lower esti-
mate than an accumulation of deficits approach using 
an index (FI) or another multi-dimensional instrument 
(e.g. GFI) [37]. 
This review has a number of limitations. Although the 
approach to reviewing the literature used was standard-
ized and the most important databases included, some 
papers may potentially have been missed. However, we 
included a very large number of datasets (n = 68) in 
this meta-analysis, mitigating this issue. Nevertheless, 
we are confident that most relevant results should have 
been published in peer-reviewed literature, and there-
fore, captured in our systematic review. Finally, there 
was a significant heterogeneity in the results as evi-
denced by the Higgin’s I2 value approaching 100%, in-
herent to the heteregenous population included in the 
studies. However, this heterogeneity could support the 
generalizability of the results for MS of JA. This degree 
of heterogeneity has been found in other similar meta-
analysis of frailty prevalence rates e.g. that in low and 
middle-income countries [34].
CONCLUSIONS
The results of this systematic review and meta-anlysis 
show that frailty is common in European countries and 
varies by setting and definition of frailty. More studies 
are required to establish the prevalence rates of frailty 
in EU JA ADVANTAGE MSs. Prevalence data disag-
gregated by age, gender, socioeconomic and frailty se-
verity status are of utmost importance to provide a reli-
able epidemiological picture of frailty. Further, as most 
data were available from community-based longitudinal 
studies and cross-sectional population-based surveys, 
more studies in different settings are required. Until 
a consensus definition of frailty is accepted and in an 
attempt to improve comparability and generalisability, 
studies should measure both the Frailty Phenotype and 
a FI with a standardised number of age-related health 
deficits e.g. 32 items. The inclusion of a common frailty 
instrument in national health surveys could contribute 
to the availability of more comparable population-based 
data at EU level, especially if this could be integrated in 
the European Health Interview Survey (EHIS), which 
is regulated by the European Commission and already 
collects comparable data across different domains 
(health status, health determinants, use of health care). 
It could also be incorporated into the European Health 
Examination Survey (EHES) funded by the European 
Commission. 
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Overall, well-designed and suitably powered preva-
lence studies of frailty at European level are necessary. 
The paucity and heterogeneity of data highlights the 
need to approach this in a standardised and harmo-
nized way across the EU. Ongoing and future longitu-
dinal studies could be adapted to support this. 
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